Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triplet therapy (ADT + darolutamide + biweekly docetaxel) for high-risk metastatic castration-sensitive prostate cancer
jRCTs041240151Phase 2Recruiting
- Start
- Jan 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darolutamide and docetaxel in prostate cancer (PCa). Primary endpoint: PSA response rate. Started Jan 2025; status: recruiting.
02
Drugs
darolutamidedocetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCTs041240151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041240151.